ROGER MONTGOMERY3h
ResMed’s half-year FY25 results: solid growth & expanding opportunities
ResMed’s (ASX:RMD) half-year FY25 results reflect a company that is not only thriving in its core business but is also ...
ROGER MONTGOMERY17h
Some selling is on the way
Continue reading → ...